Drugs that contain Nepafenac
1. List of Ilevro drug patents
ILEVRO's oppositions filed in EPO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947295 | NOVARTIS | Ophthalmic compositions containing a synergistic combination of two polymers |
Jun, 2024
(a year from now) | |
| US9662398 | NOVARTIS | Carboxylvinyl polymer-containing nanoparticle suspensions |
Dec, 2030
(7 years from now) | |
| US8921337 | NOVARTIS | Carboxyvinyl polymer-containing nanoparticle suspensions |
Mar, 2032
(8 years from now) | |
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
How can I launch a generic of ILEVRO before it's patent expiration?
More Information on Dosage
ILEVRO family patents
13
United States
8
European Union
7
Canada
7
Korea, Republic of
7
Japan
6
Spain
4
Poland
4
Slovenia
4
Denmark
4
Australia
4
Portugal
3
Hong Kong
3
Cyprus
2
Brazil
2
China
2
RS
2
Croatia
2
Hungary
2
Argentina
2
Mexico
2
South Africa
1
Chile
1
Taiwan
1
Lithuania
1
Uruguay
1
Russia
2. List of Nevanac drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071648 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
| US8324281 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
| US7834059 | NOVARTIS | Topical nepafenac formulations |
Jan, 2027
(3 years from now) | |
Market Authorisation Date: 19 August, 2005
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
More Information on Dosage
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic